Relay Therapeutics, Inc.: net deferred tax assets

What this measure means

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

Exact concept: us-gaap:DeferredTaxAssetsNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2019-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• Relay Therapeutics, Inc.: total assets
• Relay Therapeutics, Inc.: total liabilities
• Relay Therapeutics, Inc.: stockholders equity
• Relay Therapeutics, Inc.: cash and cash equivalents
• Relay Therapeutics, Inc.: net income or loss
• Relay Therapeutics, Inc.: operating cash flow
• Relay Therapeutics, Inc.: capital expenditure payments
• Relay Therapeutics, Inc.: revenue
• Relay Therapeutics, Inc.: contract revenue excluding tax
• Relay Therapeutics, Inc.: financing cash flow
• Relay Therapeutics, Inc.: investing cash flow
• Relay Therapeutics, Inc.: retained earnings or deficit
• Relay Therapeutics, Inc.: basic weighted-average shares
• Relay Therapeutics, Inc.: diluted weighted-average shares
• Relay Therapeutics, Inc.: basic earnings per share
• Relay Therapeutics, Inc.: diluted earnings per share
• Relay Therapeutics, Inc.: net property, plant and equipment
• Relay Therapeutics, Inc.: share-based compensation expense
• Relay Therapeutics, Inc.: operating income or loss
• Relay Therapeutics, Inc.: current assets
• Relay Therapeutics, Inc.: current liabilities
• Relay Therapeutics, Inc.: current accounts payable
• Relay Therapeutics, Inc.: net current accounts receivable
• Relay Therapeutics, Inc.: operating expenses
• Relay Therapeutics, Inc.: common shares outstanding
• Relay Therapeutics, Inc.: cash including restricted cash
• Relay Therapeutics, Inc.: additional paid-in capital
• Relay Therapeutics, Inc.: accumulated other comprehensive income or loss
• Relay Therapeutics, Inc.: operating lease right-of-use asset
• Relay Therapeutics, Inc.: gross property, plant and equipment
• Relay Therapeutics, Inc.: accumulated depreciation on property, plant and equipment
• Relay Therapeutics, Inc.: accrued current liabilities
• Relay Therapeutics, Inc.: prepaid expenses and other current assets
• Relay Therapeutics, Inc.: comprehensive income or loss
• Relay Therapeutics, Inc.: net income available to common stockholders
• Relay Therapeutics, Inc.: general and administrative expense
• Relay Therapeutics, Inc.: depreciation expense
• Relay Therapeutics, Inc.: other nonoperating income or expense
• Relay Therapeutics, Inc.: proceeds from issuing common stock
• Relay Therapeutics, Inc.: change in accounts receivable
• Relay Therapeutics, Inc.: change in accounts payable

Inspect the source

Entity

Relay Therapeutics, Inc. / CIK 0001812364

Captured

2026-09-21T17:28:35.832Z

SEC response SHA-256

fa0ec3b1c0571cd4da863c44bbdb1520425bab59f97c5e5a22af9eac1a936917

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001812364.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))